Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.
Oral capecitabine (Xeloda) is an effective drug with favourable safety in adjuvant and metastatic colorectal cancer. Oxaliplatin-based therapy is becoming standard for Dukes' C colon cancer in patients suitable for combination therapy, but is not yet approved by the UK National Institute for He...
मुख्य लेखकों: | Cassidy, J, Douillard, J, Twelves, C, McKendrick, J, Scheithauer, W, Bustová, I, Johnston, P, Lesniewski-Kmak, K, Jelic, S, Fountzilas, G, Coxon, F, Díaz-Rubio, E, Maughan, T, Malzyner, A, Bertetto, O, Beham, A, Figer, A, Dufour, P, Patel, K, Cowell, W, Garrison, L |
---|---|
स्वरूप: | Journal article |
भाषा: | English |
प्रकाशित: |
2006
|
समान संसाधन
-
Pharmacoeconomic analysis of Capecitabine in the adjuvant setting. Results from the X-ACT trial comparing capecitabine with 5-FU/LV in patients with Dukes' C colon cancer
द्वारा: Douillard, J, और अन्य
प्रकाशित: (2004) -
Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts).
द्वारा: Diaz-Rubio, E, और अन्य
प्रकाशित: (2004) -
Capecitabine (X) and oxaliplatin (O) combination chemotherapy in patients (pts) with advanced gall bladder or biliary tract cancer: A phase II study
द्वारा: Evans, T, और अन्य
प्रकाशित: (2006) -
Pharmacoeconomic analysis of trastuzumab emtanzine comparing to lapatinib + capecitabine in pa-tients with HER2+ breast cancer and central nervous system metastases
द्वारा: A. S. Kolbin, और अन्य
प्रकाशित: (2018-05-01) -
Understanding the need of LV pressure for the estimation of LV diastolic functions
द्वारा: Xi, J, और अन्य
प्रकाशित: (2012)